HORSHAM, Pa.--(BUSINESS WIRE)--Acurian, Inc., a leading, full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD, announced today that Paul Mitchel has joined the company as director of direct response marketing for Europe, the Middle East and Africa. In this role, Mitchel will continue to expand Acurian’s capabilities to recruit participants for clinical trials outside North America.
“Paul brings 20 years of extensive experience delivering effective direct response marketing strategies and tactics,” said Roger Smith, Acurian’s senior vice president of operations. “His background in database and relationship marketing enables Acurian to continue expanding upon our already established global support.”
The company has been active globally for a number of years and has recently seen a surge in patient enrollment and retention services particularly in Western Europe, South Africa and Australasia.
Mitchel is based in Cambridge, United Kingdom, and is initially focusing on expanding Acurian’s performance-based marketing model throughout Europe. By hyper-localizing its outreach efforts within each country, Acurian expects to reach more patients who may benefit from clinical trials, and do so more cost-effectively.
Mitchel earned a bachelor’s degree in business studies/computer science from the University of Westminster and received a diploma in interactive/direct marketing from the Institute of Direct and Digital Marketing. He has won an IPA Effectiveness Award from the Institute of Practitioners in Advertising and an IDM Business Performance Award from the Institute of Direct and Digital Marketing.
About Acurian
Acurian, a subsidiary of PPD, is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time.
About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Acurian’s service offerings and expertise, including outside the United States, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD and Acurian attempt to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development and privacy laws and regulations; changes in the regulation of the drug development process and privacy laws and regulations; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD and Acurian do not assume any obligation and expressly disclaim any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s or Acurian’s estimates or views as of any date subsequent to the date hereof.
